Kommentar zu „Polypille überzeugt in der Sekundärprävention“

• Literatur

• 1 Kotseva K, De Backer G, De Bacquer D. et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol 2019; 26: 824-835
• 2 Gupta P, Patel P, Strauch B. et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension 2017; 69: 1113-1120
• 3 Bahiru E, de Cates AN, Farr MR. et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 3: CD009868
• 4 Joseph P, Roshandel G, Gao P. et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet (London, England) 2021; 398: 1133-1146
• 5 Castellano JM, Pocock SJ, Bhatt DL. et al. Polypill Strategy in Secondary Cardiovascular Prevention. The New England journal of medicine 2022; 387: 967-977